New anti-cancer drug extends life of melanoma victims

A new experimental drug developed by Bristol-Myers Squibb and Medarex extends the lives of patients with advanced melanoma, the deadliest form of skin cancer, researchers said.

The results paved the way for dealing with a form of cancer that has few treatment options. Melanoma cases have climbed faster than any other cancer type over the past 30 years, researchers said.

Nearly a quarter - 24 percent - of patients with advanced melanoma survived for an unusual two years after being administered intravenously with ipilimumab.

Forty-four to 46 percent of patients treated with ipilimumab were alive after one year of trials compared to 25 percent of patients treated with other methods, the study pointed out.

"Randomized clinical trials have repeatedly failed to demonstrate an improvement in overall survival in patients with advanced melanoma," said lead author Steven O'Day, who heads the melanoma program at The Angeles Clinic and Research Institute in southern California.

O'Day described the study findings as "an exciting advance, both for patients with advanced melanoma and for the field of cancer immunology."

He presented the study at the American Society of Clinical Oncology meeting this weekend in Chicago.

Lynn Schuchter, professor of medicine at Abramson Cancer Center at the University of Pennsylvania, said these findings were "really exciting" because ipilimumab and other new cancer drugs produced far fewer side effects than traditional chemotherapy.

"This drug takes the brake off and allows for further immunological response, and this is going to be the first time that a trial with patients with advanced melanoma shows a survival benefit," Schuchter said.

She noted that just six months ago, doctors really had no effective therapy for patients with stage 4 melanoma.

Ipilimumab belongs to a new class of drugs that activate the immune system's T cells, which then seek and destroy melanoma cells, instead of targeting the cancer cell itself like previous treatments.

In the clinical test, patients who took ipilimumab or were treated with a combination of the antibody and a peptide vaccine, also aimed at boosting the immune system, lived a median of 10 months, against 6.5 months for those administered a placebo or a peptide vaccine alone.

The Phase III clinical trial studied some 600 melanoma patients in several countries. Patients generally tolerated the treatment well, the researchers said.

Experts pointed out that given the success of the trials, the US Food and Drug Administration was expected to grant permission to market the medicine relatively quickly.

Ipilimumab was forecast to generate more than 400 million dollars in sales in the first several years following its approval.

Melanoma is one of the deadliest forms of cancer, and the number of people affected by it has been increasing for 30 years, according to the World Health Organization.

Skin cancer annually kills 66,000 people around the world, the WHO said, and 80 percent of these deaths are attributable to melanoma.

As many as 68,000 new cases of melanoma were diagnosed in the United States last year, and about 8,600 people died of the disease.

In France, 7,000 cases of melanoma are detected each year, and an average of 1,300 of them have a fatal outcome.

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Project and Quality Manager

    £28000 - £32000 per annum: Recruitment Genius: This company is an independent ...

    Recruitment Genius: Trainee Sales Executive - OTE £20,625

    £14625 - £20625 per annum: Recruitment Genius: This role is for an enthusiasti...

    Guru Careers: Financial Controller

    £45 - £55k DOE: Guru Careers: A Financial Controller is required to join a suc...

    Recruitment Genius: Fertility Nurse

    Negotiable: Recruitment Genius: This is an exciting opportunity to join the ho...

    Day In a Page

    Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

    Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

    Turkish President Erdogan could benefit politically from the targeting of the PKK, says Patrick Cockburn
    Yvette Cooper: Our choice is years of Tory rule under Jeremy Corbyn or a return to a Labour government

    Our choice is years of Tory rule under Corbyn or a return to a Labour government

    Yvette Cooper urged Labour members to 'get serious' about the next general election rather than become 'a protest movement'
    Singapore's domestic workers routinely exploited and often abused in the service of rich nationals

    Singapore's hidden secret of domestic worker abuse

    David Cameron was shown the country's shiniest veneer on his tour. What he didn't see was the army of foreign women who are routinely exploited and often abused in the service of rich nationals
    Showdown by Shirley Jackson: A previously unpublished short story from the queen of American Gothic

    Showdown, by Shirley Jackson

    A previously unpublished short story from the queen of American Gothic
    10 best DSLRs

    Be sharp! 10 best DSLRs

    Up your photography game with a versatile, powerful machine
    Solved after 200 years: the mysterious deaths of 3,000 soldiers from Napoleon's army

    Solved after 200 years

    The mysterious deaths of 3,000 soldiers from Napoleon's army
    Every regional power has betrayed the Kurds so Turkish bombing is no surprise

    Robert Fisk on the Turkey conflict

    Every regional power has betrayed the Kurds so Turkish bombing is no surprise
    Investigation into wreck of unidentified submarine found off the coast of Sweden

    Sunken sub

    Investigation underway into wreck of an unidentified submarine found off the coast of Sweden
    Instagram and Facebook have 'totally changed' the way people buy clothes

    Age of the selfie

    Instagram and Facebook have 'totally changed' the way people buy clothes
    Not so square: How BBC's Bloomsbury saga is sexing up the period drama

    Not so square

    How Virginia Woolf saga is sexing up the BBC period drama
    Rio Olympics 2016: The seven teenagers still carrying a torch for our Games hopes

    Still carrying the torch

    The seven teenagers given our Olympic hopes
    The West likes to think that 'civilisation' will defeat Isis, but history suggests otherwise

    The West likes to think that 'civilisation' will defeat Isis...

    ...but history suggests otherwise
    The bald truth: How one author's thinning hair made him a Wayne Rooney sympathiser

    The bald truth

    How thinning hair made me a Wayne Rooney sympathiser
    Froome wins second Tour de France after triumphant ride into Paris with Team Sky

    Tour de France 2015

    Froome rides into Paris to win historic second Tour
    Fifteen years ago, Concorde crashed, and a dream died. Today, the desire to travel faster than the speed of sound is growing once again

    A new beginning for supersonic flight?

    Concorde's successors are in the works 15 years on from the Paris crash